The potential significance of high avidity immunoglobulin G (IgG) for protective immunity towards SARS-CoV-2

被引:53
作者
Bauer, Georg [1 ,2 ]
机构
[1] Univ Freiburg, Inst Virol, Med Ctr, Freiburg, Germany
[2] Univ Freiburg, Fac Med, Freiburg, Germany
关键词
SARS-CoV-2; Covid-19; Avidity; Protective immunity; Vaccination; Neutralizing antibody; ANTIBODY-RESPONSES; INFECTION; MATURATION; WOMEN; DIFFERENTIATION; CHILDREN; IMPAIRS; CELL;
D O I
10.1016/j.ijid.2021.01.061
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Avidity is defined as the strength of binding between immunoglobulin G (IgG) and its specific target epitope. IgG of high avidity is established during affinity maturation. Failure to achieve high avidity IgG may result in a lack of protective immunity towards infection and disease. It is known that the interaction between SARS-CoV-2 spike protein and its cellular receptor is driven by high affinity. Therefore, it is predictable that protective antibodies towards SARS-CoV-2 should show high affinity/ avidity. Avidity after SARS-CoV-2 infection: Recent findings by several groups demonstrate that the serological response towards infection with SARS-CoV-2 and seasonal coronaviruses is characterized by incomplete avidity maturation, followed by a decline of the serological response. This response might facilitate reinfection, prevent herd immunity and potentially allow repeated cycles of infection. Consequences for vaccination towards SARS-CoV-2: Therefore, the sole focus on antibody titers reached after vaccination towards SARS-CoV-2 might not be sufficient to evaluate the degree of achieved protection. Rather, it is suggested to include avidity determination to optimize vaccination protocols and achieve high avidity IgG directed towards SARS-CoV-2 through vaccination. Avidity determination might also be useful to control for truly protective immunity towards SARS-CoV-2 in individual cases. (c) 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
引用
收藏
页码:61 / 64
页数:4
相关论文
共 47 条
[1]   SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies [J].
Barnes, Christopher O. ;
Jette, Claudia A. ;
Abernathy, Morgan E. ;
Dam, Kim-Marie A. ;
Esswein, Shannon R. ;
Gristick, Harry B. ;
Malyutin, Andrey G. ;
Sharaf, Naima G. ;
Huey-Tubman, Kathryn E. ;
Lee, Yu E. ;
Robbiani, Davide F. ;
Nussenzweig, Michel C. ;
West, Anthony P., Jr. ;
Bjorkman, Pamela J. .
NATURE, 2020, 588 (7839) :682-+
[2]  
Barnes CO, 2020, CELL, V182, P828, DOI [10.1016/j.cell.2020.06.025, 10.1101/2020.05.28.121533]
[3]  
Bauer G., 2020, RES SQUARE, DOI [10.21203/rs.3.rs-104847/v1, DOI 10.21203/RS.3.RS-104847/V1]
[4]   The challenge of avidity determination in SARS-CoV-2 serology [J].
Bauer, Georg ;
Struck, Friedhelm ;
Schreiner, Patrick ;
Staschik, Eva ;
Soutschek, Erwin ;
Motz, Manfred .
JOURNAL OF MEDICAL VIROLOGY, 2021, 93 (05) :3092-3104
[5]   The variability of the serological response to SARS-corona virus-2: Potential resolution of ambiguity through determination of avidity (functional affinity) [J].
Bauer, Georg .
JOURNAL OF MEDICAL VIROLOGY, 2021, 93 (01) :311-322
[6]   Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals [J].
Beaudoin-Bussieres, Guillaume ;
Laumaea, Annemarie ;
Anand, Sai Priya ;
Prevost, Jeremie ;
Gasser, Romain ;
Goyette, Guillaume ;
Medjahed, Halima ;
Perreault, Josee ;
Tremblay, Tony ;
Lewin, Antoine ;
Gokool, Laurie ;
Morrisseau, Chantal ;
Begin, Philippe ;
Tremblay, Cecile ;
Martel-Laferriere, Valerie ;
Kaufmann, Daniel E. ;
Richard, Jonathan ;
Bazin, Renee ;
Finzi, Andres .
MBIO, 2020, 11 (05) :1-7
[7]   SARS-CoV-2 Antibody Avidity Responses in COVID-19 Patients and Convalescent Plasma Donors [J].
Benner, Sarah E. ;
Patel, Eshan U. ;
Laeyendecker, Oliver ;
Pekosz, Andrew ;
Littlefield, Kirsten ;
Eby, Yolanda ;
Fernandez, Reinaldo E. ;
Miller, Jernelle ;
Kirby, Charles S. ;
Keruly, Morgan ;
Klock, Ethan ;
Baker, Owen R. ;
Schmidt, Haley A. ;
Shrestha, Ruchee ;
Burgess, Imani ;
Bonny, Tania S. ;
Clarke, William ;
Caturegli, Patrizio ;
Sullivan, David ;
Shoham, Shmuel ;
Quinn, Thomas C. ;
Bloch, Evan M. ;
Casadevall, Arturo ;
Tobian, Aaron A. R. ;
Redd, Andrew D. .
JOURNAL OF INFECTIOUS DISEASES, 2020, 222 (12) :1974-1984
[8]   ANTIVIRAL ANTIBODY-RESPONSES AND INTRAUTERINE TRANSMISSION AFTER PRIMARY MATERNAL CYTOMEGALOVIRUS-INFECTION [J].
BOPPANA, SB ;
BRITT, WJ .
JOURNAL OF INFECTIOUS DISEASES, 1995, 171 (05) :1115-1121
[9]   THE TIME COURSE OF THE IMMUNE-RESPONSE TO EXPERIMENTAL CORONAVIRUS INFECTION OF MAN [J].
CALLOW, KA ;
PARRY, HF ;
SERGEANT, M ;
TYRRELL, DAJ .
EPIDEMIOLOGY AND INFECTION, 1990, 105 (02) :435-446
[10]   Antibody avidity maturation during severe acute respiratory syndrome-associated coronavirus infection [J].
Chan, PKS ;
Lim, PL ;
Liu, EYM ;
Cheung, JLK ;
Leung, DTM ;
Sung, JJY .
JOURNAL OF INFECTIOUS DISEASES, 2005, 192 (01) :166-169